In honor of Rare Disease Day, we discuss news from Healx, a clinical-stage biotech, which has dosed the first patient in a Phase II trial of its new drug for neurofibromatosis type 1. In the world of AI, the Arc Institute in collaboration with Nvidia has dropped Evo 2, the “largest publicly accessible AI model for biology to date,” for designing genomes. Additionally, new work from Nobel Laureate, David Baker, uses AI to generate enzymes from scratch. We also dig into the big announcements from Illumina and Roche that got the community buzzing ahead of this year’s AGBT meeting.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Healx Candidate, SpringWorks Therapy Expand NF1 Treatment Options

By Alex Philippidis, GEN Edge, February 25, 2025

Arc Institute’s AI Model Evo 2 Designs the Genetic Code Across All Domains of Life

By Fay Lin, PhD, GEN Edge, February 19, 2025

AI-Driven Protein Design Produces Enzyme that Mimics Natural Hydrolase Activity

By Corinna Singleman, PhD, GEN, February 13, 2025

Illumina Unveils Spatial Technology Days Before AGBT Meeting

By Julianna LeMieux, PhD, GEN, February 19, 2025

StockWatch: Illumina Tumbles on Q4 Results, China Retaliation

By Alex Philippidis, GEN Edge, February 8, 2025

Roche Announces SBX Technology, Creates Sequencing Buzz

By Julianna LeMieux, PhD, GEN, February 21, 2025

StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks 

By Alex Philippidis, GEN Edge, February 17, 2025

Hosted on Acast. See acast.com/privacy for more information.